Aeglea Bio Ownership
The majority of Aeglea Bio Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aeglea Bio Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aeglea Bio. Please pay attention to any change in the institutional holdings of Aeglea Bio Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Aeglea |
Aeglea Stock Ownership Analysis
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. For more info on Aeglea Bio Therapeutics please contact James JD at 512 942 2935 or go to https://www.aeglea.com.Aeglea Bio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aeglea Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aeglea Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aeglea Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stelzer Laurie over a year ago Acquisition by Stelzer Laurie of 50000 shares of Aeglea Bio subject to Rule 16b-3 | ||
Smith Hunter C over a year ago Acquisition by Smith Hunter C of 1950000 shares of Aeglea Bio subject to Rule 16b-3 |
Aeglea Bio Outstanding Bonds
Aeglea Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aeglea Bio Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aeglea bonds can be classified according to their maturity, which is the date when Aeglea Bio Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US00775PAA57 Corp BondUS00775PAA57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAG06 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAE57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAB19 | View | |
| AER 385 29 OCT 41 Corp BondUS00774MAZ86 | View | |
| AER 33 30 JAN 32 Corp BondUS00774MAX39 | View | |
| AER 34 29 OCT 33 Corp BondUS00774MAY12 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |